RT Journal Article
SR Electronic
T1 Mutation prevalence tables for hereditary cancer derived from multi-gene panel testing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19011981
DO 10.1101/19011981
A1 Hart, Steven N.
A1 Polley, Eric C.
A1 Yussuf, Amal
A1 Yadav, Siddhartha
A1 Goldgar, David E.
A1 Hu, Chunling
A1 LaDuca, Holly
A1 Smith, Laura P.
A1 Fujimoto, June
A1 Li, Shuwei
A1 Couch, Fergus J.
A1 Dolinsky, Jill S.
YR 2019
UL http://medrxiv.org/content/early/2019/11/15/19011981.abstract
AB Purpose Multi-gene panel testing for cancer predisposition mutations is becoming routine in clinical care. However, the gene content of panels offered by testing laboratories vary significantly, and data on mutation detection rates by gene and by panel is limited, causing confusion among clinicians on which test would be the most appropriate to order. Moreover, screening guidelines are not described in sufficient granularity to explain how differences in family, personal history, age, and other factors would affect the prevalence of finding a mutation in similar populations. The tool herein quantifies prevalence of mutations in hereditary cancer genes based on personalized clinical and demographic characteristics.Methods Using results from approximately 150,000 multi-gene panel tests conducted at Ambry Genetics, we built an interactive prevalence tool to explore how differences in ethnicity, age of onset, and personal and family history of different cancers affect the prevalence of pathogenic mutations in 31 cancer predisposition genes, across various clinically available hereditary cancer gene panels.Results Over 13,000 mutation carriers were identified in this high-risk population. Most of the cases were Non-Hispanic White (74%, n=109,537), but also provide an appreciable dataset for those identifying as Black (n=10,875), Ashkenazi Jewish (n=10,464), Hispanic (n=10,028), and Asian (n=7,090). The most prevalent cancer types were breast (50%), ovarian (6.6%), and colorectal (4.7%), which is expected based on genetic testing guidelines and clinician referral for testing.Conclusion The Hereditary Cancer Multi-Gene Panel Prevalence Tool presented here can be used to provide insight into the prevalence of mutations on a per-gene and per-multigene panel basis, while conditioning on multiple custom phenotypic variables to include race and cancer type. The tool can be found at https://www.ambrygen.com/prevalence-tool.Competing Interest StatementJSD, JF, LPS, SL, HL, and AY are all employees of Ambry Genetics.Funding StatementThis work was funded by the Breast Cancer Research Foundation (BCRF #16-030), NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201], and the Mayo Clinic Center for Individualized Medicine.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe website is available at https://www.ambrygen.com/clinician/resources/prevalence-tool https://www.ambrygen.com/clinician/resources/prevalence-tool